gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Pattern of recurrence in patients with glioblastoma multiforme treated with an antiangiogenic therapy

Lokalisation der Rezidive von antiangiogen behandelten Patienten mit Glioblastoma multiforme

Meeting Abstract

  • corresponding author J. Tüttenberg - Neurochirurgische Klinik, Universitätsklinikum Mannheim
  • R. Grobholz - Institut für Pathologie, Universitätsklinikum Mannheim
  • T. Korn - Neurochirurgische Klinik, Universitätsklinikum Mannheim
  • F. Wenz - Radioonkologische Klinik, Universitätsklinikum Mannheim
  • R. Erber - Neurochirurgische Klinik, Universitätsklinikum Mannheim
  • P. Vajkoczy - Neurochirurgische Klinik, Universitätsklinikum Mannheim

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc09.05.-18.05

The electronic version of this article is the complete one and can be found online at:

Published: May 4, 2005

© 2005 Tüttenberg et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.




Glioblastoma multiforme is the prototype of an angiogenic tumour and thus predestined for antiangiogenic therapy. But a possible escape mechanism of tumour cells is increased invasion. The aim of this study was to evaluate the progression free- and overall-survival in patients with glioblastoma multiforme treated with continuous low dose chemotherapy with temozolomide and rofecoxib with special respect to the localisation of tumour recurrence.


22 Patients with glioblastoma multiforme received after operation and radiation therapy continuous low dose chemotherapy with temozolomide (up to 20mg/m2) and the COX-II inhibitor rofecoxib. Clinical and MRI follow-up examination was done every 8 weeks. Mean follow-up time was 20 months. Tumour tissue was analysed for microvessel density, COX-II expression and VEGF expression in 13 patients.


Mean progression-free survival of all patients was 9.7 months, mean overall survival was 16.9 months. 14 out of 22 Patients (67%) suffered a tumour recurrence distant to the original tumour-localisation. These patients had a slightly shorter overall survival. Patients with a higher microvessel density responded significantly better to the therapy (PFS 11.7 vs. 6.7 months). There was no relationship of the immunhistochemical markers and the incidence of distant tumour recurrence.


Despite the dramatic increase in distant tumour recurrences compared to historical controls the continuous low dose chemotherapy seems to be a promising therapy option in highly vascularised glioblastoma since the progression-free survival and the overall survival compare very well to actual studies.